ID: ALA418799

Max Phase: Preclinical

Molecular Formula: C20H20N2O

Molecular Weight: 304.39

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1Nc2ccccc2/C1=C\c1ccc(N2CCCCC2)cc1

Standard InChI:  InChI=1S/C20H20N2O/c23-20-18(17-6-2-3-7-19(17)21-20)14-15-8-10-16(11-9-15)22-12-4-1-5-13-22/h2-3,6-11,14H,1,4-5,12-13H2,(H,21,23)/b18-14+

Standard InChI Key:  YKIYMEVKKILHAK-NBVRZTHBSA-N

Associated Targets(non-human)

Vascular endothelial growth factor receptor 2 134 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 304.39Molecular Weight (Monoisotopic): 304.1576AlogP: 4.17#Rotatable Bonds: 2
Polar Surface Area: 32.34Molecular Species: NEUTRALHBA: 2HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.31CX Basic pKa: 5.18CX LogP: 4.22CX LogD: 4.22
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.84Np Likeness Score: -0.77

References

1. Vieth M, Cummins DJ..  (2000)  DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors.,  43  (16): [PMID:10956210] [10.1021/jm990609e]

Source